Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
35
EVFM Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
-4.11%
Day range:
$0.0095 - $0.0106
52-week range:
$0.0060 - $0.0200
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.93x
P/B ratio:
--
Volume:
661.4K
Avg. volume:
218.5K
1-year change:
5.53%
Market cap:
$1.3M
Revenue:
$19.4M
EPS (TTM):
-$0.06
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
EVFM
Evofem Biosciences, Inc.
|
-- | -- | -- | -- | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.20 | -- | -26.67% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
EVFM
Evofem Biosciences, Inc.
|
$0.0103 | -- | $1.3M | -- | $0.00 | 0% | 0.93x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.30 | $0.85 | $667.9M | 8.90x | $0.80 | 0% | 10.30x |
|
NNVC
NanoViricides, Inc.
|
$1.24 | $6.50 | $22.3M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.88 | $2.00 | $722.3K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.4M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
EVFM
Evofem Biosciences, Inc.
|
-289.33% | 0.633 | 815.18% | 0.07x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
EVFM
Evofem Biosciences, Inc.
|
$4M | -$982K | -- | -- | -19.83% | $336K |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Evofem Biosciences, Inc. vs. Competitors
-
Which has Higher Returns EVFM or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -31.68% compared to Evofem Biosciences, Inc.'s net margin of -255.85%. Evofem Biosciences, Inc.'s return on equity of -- beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital EVFMEvofem Biosciences, Inc.80.11% -$0.01 -$18M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About EVFM or NBY?
Evofem Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 2184366.02%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Evofem Biosciences, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Evofem Biosciences, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EVFMEvofem Biosciences, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is EVFM or NBY More Risky?
Evofem Biosciences, Inc. has a beta of -1.277, which suggesting that the stock is 227.683% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock EVFM or NBY?
Evofem Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Evofem Biosciences, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVFM or NBY?
Evofem Biosciences, Inc. quarterly revenues are $5M, which are larger than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Evofem Biosciences, Inc.'s net income of -$1.6M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Evofem Biosciences, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evofem Biosciences, Inc. is 0.93x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVFMEvofem Biosciences, Inc.0.93x -- $5M -$1.6M NBYNovaBay Pharmaceuticals, Inc.10.30x 8.90x $521K -$1.3M
-
Which has Higher Returns EVFM or NNVC?
NanoViricides, Inc. has a net margin of -31.68% compared to Evofem Biosciences, Inc.'s net margin of --. Evofem Biosciences, Inc.'s return on equity of -- beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital EVFMEvofem Biosciences, Inc.80.11% -$0.01 -$18M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About EVFM or NNVC?
Evofem Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 2184366.02%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 424.19%. Given that Evofem Biosciences, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Evofem Biosciences, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EVFMEvofem Biosciences, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is EVFM or NNVC More Risky?
Evofem Biosciences, Inc. has a beta of -1.277, which suggesting that the stock is 227.683% less volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock EVFM or NNVC?
Evofem Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evofem Biosciences, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVFM or NNVC?
Evofem Biosciences, Inc. quarterly revenues are $5M, which are larger than NanoViricides, Inc. quarterly revenues of --. Evofem Biosciences, Inc.'s net income of -$1.6M is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Evofem Biosciences, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evofem Biosciences, Inc. is 0.93x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVFMEvofem Biosciences, Inc.0.93x -- $5M -$1.6M NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns EVFM or OGEN?
Oragenics, Inc. has a net margin of -31.68% compared to Evofem Biosciences, Inc.'s net margin of --. Evofem Biosciences, Inc.'s return on equity of -- beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital EVFMEvofem Biosciences, Inc.80.11% -$0.01 -$18M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About EVFM or OGEN?
Evofem Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 2184366.02%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 127.84%. Given that Evofem Biosciences, Inc. has higher upside potential than Oragenics, Inc., analysts believe Evofem Biosciences, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EVFMEvofem Biosciences, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is EVFM or OGEN More Risky?
Evofem Biosciences, Inc. has a beta of -1.277, which suggesting that the stock is 227.683% less volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock EVFM or OGEN?
Evofem Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evofem Biosciences, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVFM or OGEN?
Evofem Biosciences, Inc. quarterly revenues are $5M, which are larger than Oragenics, Inc. quarterly revenues of --. Evofem Biosciences, Inc.'s net income of -$1.6M is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Evofem Biosciences, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evofem Biosciences, Inc. is 0.93x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVFMEvofem Biosciences, Inc.0.93x -- $5M -$1.6M OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns EVFM or PTN?
Palatin Technologies has a net margin of -31.68% compared to Evofem Biosciences, Inc.'s net margin of --. Evofem Biosciences, Inc.'s return on equity of -- beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital EVFMEvofem Biosciences, Inc.80.11% -$0.01 -$18M PTNPalatin Technologies-- -- -- -
What do Analysts Say About EVFM or PTN?
Evofem Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 2184366.02%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Evofem Biosciences, Inc. has higher upside potential than Palatin Technologies, analysts believe Evofem Biosciences, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings EVFMEvofem Biosciences, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is EVFM or PTN More Risky?
Evofem Biosciences, Inc. has a beta of -1.277, which suggesting that the stock is 227.683% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock EVFM or PTN?
Evofem Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evofem Biosciences, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVFM or PTN?
Evofem Biosciences, Inc. quarterly revenues are $5M, which are larger than Palatin Technologies quarterly revenues of --. Evofem Biosciences, Inc.'s net income of -$1.6M is higher than Palatin Technologies's net income of --. Notably, Evofem Biosciences, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evofem Biosciences, Inc. is 0.93x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVFMEvofem Biosciences, Inc.0.93x -- $5M -$1.6M PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns EVFM or TOVX?
Theriva Biologics, Inc. has a net margin of -31.68% compared to Evofem Biosciences, Inc.'s net margin of --. Evofem Biosciences, Inc.'s return on equity of -- beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital EVFMEvofem Biosciences, Inc.80.11% -$0.01 -$18M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About EVFM or TOVX?
Evofem Biosciences, Inc. has a consensus price target of --, signalling upside risk potential of 2184366.02%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3570.69%. Given that Evofem Biosciences, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Evofem Biosciences, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings EVFMEvofem Biosciences, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is EVFM or TOVX More Risky?
Evofem Biosciences, Inc. has a beta of -1.277, which suggesting that the stock is 227.683% less volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock EVFM or TOVX?
Evofem Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Evofem Biosciences, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios EVFM or TOVX?
Evofem Biosciences, Inc. quarterly revenues are $5M, which are larger than Theriva Biologics, Inc. quarterly revenues of --. Evofem Biosciences, Inc.'s net income of -$1.6M is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Evofem Biosciences, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Evofem Biosciences, Inc. is 0.93x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income EVFMEvofem Biosciences, Inc.0.93x -- $5M -$1.6M TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 20
Lamb Weston Holdings, Inc. [LW] is down 25.96% over the past day.
Buy
54
BMRN alert for Dec 20
BioMarin Pharmaceutical, Inc. [BMRN] is up 17.79% over the past day.
Buy
82
RKLB alert for Dec 20
Rocket Lab Corp. [RKLB] is up 17.72% over the past day.
